Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects

Jeffrey S Burgdorf*, Xiao Lei Zhang, Patric K. Stanton, Joseph R. Moskal, John E. Donello

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: The role of glutamatergic receptors in major depressive disorder continues to be of great interest for therapeutic development. Recent studies suggest that both negative and positive modulation of N-methyl-D-aspartate receptors (NMDAR) can produce rapid antidepressant effects. Here we report that zelquistinel, a novel NMDAR allosteric modulator, exhibits high oral bioavailability and dose-proportional exposures in plasma and the central nervous system and produces rapid and sustained antidepressant-like effects in rodents by enhancing activity-dependent, long-term synaptic plasticity. Methods: NMDAR-mediated functional activity was measured in cultured rat brain cortical neurons (calcium imaging), hNR2A or B subtype-expressing HEK cells, and synaptic plasticity in rat hippocampal and medial prefrontal cortex slices in vitro. Pharmacokinetics were evaluated in rats following oral administration. Antidepressant-like effects were assessed in the rat forced swim test and the chronic social deficit mouse model. Target engagement and the safety/tolerability profile was assessed using phencyclidine-induced hyperlocomotion and rotarod rodent models. Results: Following a single oral dose, zelquistinel (0.1–100 µg/kg) produced rapid and sustained antidepressant-like effects in the rodent depression models. Brain/ cerebrospinal fluid concentrations associated with zelquistinel antidepressant-like activity also increased NMDAR function and rapidly and persistently enhanced activity-dependent synaptic plasticity (long-term potentiation), suggesting that zelquistinel produces antidepressant-like effects by enhancing NMDAR function and synaptic plasticity. Furthermore, Zelquistinel inhibited phencyclidine (an NMDAR antagonist)-induced hyperlocomotion and did not impact rotarod performance. Conclusions: Zelquistinel produces rapid and sustained antidepressant effects by positively modulating the NMDARs, thereby enhancing long-term potentiation of synaptic transmission.

Original languageEnglish (US)
Pages (from-to)979-991
Number of pages13
JournalInternational Journal of Neuropsychopharmacology
Volume25
Issue number12
DOIs
StatePublished - Dec 1 2022

Funding

The authors thank Pradeep Banerjee, Yuan-Xin Guo, and Yong-Xin Li for their extensive contributions to this program and manuscript. Editorial assistance was provided by Katharine Fang, PhD, of Prescott Medical Communications Group (Chicago, IL, USA). This study was funded by Allergan Inc. (prior to its license agreement with Gate Neurosciences).

Keywords

  • Antidepressant
  • NMDA receptor
  • depression
  • major depressive disorder
  • synaptic plasticity
  • zelquistinel

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects'. Together they form a unique fingerprint.

Cite this